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Abstract
In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily cured
by a short course of medication. Medical breakthroughs have now created the possibility of eliminating the
transmission of HCV, but also bring a new challenge for the health system—how to identify individuals
carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief reviews
recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the case for
universal, one-time HCV screening for all US adults.
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In just five years, hepatitis C has changed from a difficult-to-treat chronic  condition to one that is readily cured by a short course of medication. Medical 
breakthroughs have now created the possibility of eliminating the transmission of 
HCV, but also bring a new challenge for the health system—how to identify  
individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving 
treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of 
screening and treatment strategies, and makes the case for universal, one-time 
HCV screening for all US adults.
Background
More than 3.5 million people in the US are chronically infected with HCV, and about 19,000 
die each year from HCV-related diseases. Hepatitis C is a leading cause of liver cancer and 
the leading cause of liver transplants; baby boomers (people born during 1945-1965) 
account for three-quarters of all cases and hepatitis C-related deaths. The incidence of HCV 
infection is rising in younger people, primarily because of injection drug use.
A high proportion (from 45% to 85%, according the CDC) are unaware that they have the 
disease, and may infect others. In 1998, the CDC recommended HCV testing only for people 
at high risk—such as a history of injection drug use or exposure to blood products before 
effective screening—a strategy that left most people unaware of their status. Because of a 
disproportionately high prevalence of hepatitis C among baby boomers, the CDC  
augmented their recommendations in 2012 to include one-time testing of all people in that 
birth cohort. In 2013 the US Preventive Services Task Force (USPSTF) gave this  
recommendation a “B” grade, which meant that the screening would be covered by  
insurance with no cost-sharing under the Affordable Care Act. A few months later, the first 
efficacious direct-acting anti-virals hit the market, offering a nearly 90% cure rate and the 
potential to eliminate transmission of HCV. That potential, however, was limited by the 
initial price tag ($84,000 per course of treatment) and the budget impact on public payers, 
such as Medicaid and Departments of Corrections, who cover a disproportionate number 
of people with HCV. In response, these payers have limited treatments to patients with 
advanced disease or used other restrictions.
In an era of effective treatments, identifying people with hepatitis C takes on even greater 
urgency as the beginning step in a “cascade of care” leading to cure, and potential  
elimination of HCV transmission. But the combination of a prevalent disease with an  
expensive cure, and the burden of treatment on public budgets, creates a significant  
economic barrier to HCV care. 
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New screening guidelines have an impact
In a study of the effects of the new CDC testing guidelines, Barocas, Wang, White, et al. 
(2017) found an “immediate and sustained impact of hepatitis C testing guidelines on  
clinical practice.” They analyzed hepatitis C screening rates in 2.8 million commercially 
insured adults before and after the recommendations, using a cohort born after 1965 (but 
at least 18 years old) as a comparison group. As shown below, they found a 49% increase in 
screening rates among the birth cohort after the release of the recommendations, but no 
increase among the comparison cohort.
   Figure 1 
   Trends in quarterly hepatitis C screening rates in the United States per 100 person-years in 2010-14, by age cohort
Rodriguez, Rubenstein, Linas, et al. (2018) confirmed the effects of the CDC and USPSTF 
screening recommendations in an observational study of 665,000 adults visiting  
Kaiser Permanente clinics between 2003 and 2014. They documented a steady increase in 
screening over time, with a noticeable jump in screening after the USPSTF  
recommendations. As shown below, HCV screening jumped 29% from 2013-2014,  
compared to 4% from 2012-2013. 
   Figure 2  
   HCV screening rate over time, Kaiser Permanente, 2003-2014
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screening raTes jump afTer 
cdc recommends hcv 
screening of all BaBy 
Boomers  
Source: Joshua A. Barocas, Jianing Wang, Laura F. White, Abriana Tasillo, Joshua A. Salomon, Kenneth A. 
Freedberg, and Benjamin P. Linas. Hepatitis C Testing Increased Among Baby Boomers Following The 2012 
Change To CDC Testing Recommendations. Health Affairs, 2017 36:12, 2142-2150
Source: Rodriguez CV, Rubenstein KB, Linas B, Hu H, Horberg M. Increasing hepatitis C screening in a 
large integrated health system: science and policy in concert. American Journal of Managed Care, 2018 May 
1;24(5):e134-e140. 
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Adjusting for other factors, the authors found that screening in the birth cohort more than 
doubled, which represented a 20% greater increase than screening in other age groups. 
The authors point out that insurance coverage for screening and the availability of effective 
treatment after the USPSTF recommendation may have led to a greater increase in  
screening than screening guidelines alone.
HCV treatment provides good value
Despite its cost, HCV treatment provides good value for the money, as expressed in terms 
of cost-effectiveness. In a recent review, Linas and Nolen (2018) note that most studies 
in the past five years find that HCV treatment falls within the generally accepted value of 
$100,000 per quality-adjusted life year (QALY). They note that these studies do not reflect 
price decreases that have occurred in the past 1-2 years—but the substantial cost burden 
remains. A critical question is not whether to treat patients with HCV, but when, because of 
the significant lag time between infection and disease. Facing costs that could overwhelm 
fixed budgets, many payers have restricted treatments to those with advanced disease  
(for example, liver cirrhosis) or those who are alcohol- or drug-free.
In one study, Linas, Morgan, Pho, et al. (2017) modeled the cost-effectiveness and  
budgetary impact of different treatment strategies, from a payer’s point of view. They 
found that the five-year budgetary impact of treating HCV was high ($1-$2.3 billion per 
10,000 HCV-infected patients, depending on the treatment regimen). They confirmed that 
the treatment strategies are cost-effective; compared to treating more advanced disease 
only, treating early disease is likely cost-effective, and may even be cost-saving, because it 
prevents many years of decreased quality of life and increased health care costs associated 
with HCV infection. They conclude that payers seeking to control costs would do better by 
price negotiations in a newly competitive drug market rather than by treatment restrictions. 
Treating all HCV-infected people with the least costly direct-acting antiviral would be the 
cost-control strategy that produces the best outcomes.
There is some evidence that public payers are relaxing their eligibility restrictions (such as 
disease severity and substance use abstinence) for hepatitis C treatment. Kapadia, Jeng, 
Schackman, and Bao (2017) looked at Medicaid drug utilization data from 2014 to 2016, 
and found that states that loosened their restrictions had a more rapid increase in  
prescriptions of direct-acting antivirals than states maintaining their restrictions. The 31 
states that implemented Medicaid expansion under the Affordable Care Act saw much 
more of an increase in utilization than states that did not.
What’s the optimal HCV screening strategy?
Using a simulation model, Barocas, Tasillo, Eftekhari Yazdi, et al. (2018) compared the  
clinical costs, outcomes, and cost-effectiveness of four HCV testing strategies: the  
existing one (one-time testing for all persons born between 1945 and 1965); one-time 
testing for adults aged 40 or higher, 30 or higher, or 18 or higher. All strategies included 
targeted testing of people at higher risk, such as those who inject drugs. As shown  
below, expanded age-based strategies increased identification and lifetime cure rates. 
compared To TreaTing more 
advanced disease only, 
TreaTing early disease is 
likely cosT-effecTive, and 
may even Be cosT-saving.
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   Figure 3 
   HCV continuum of care over a lifetime, by strategy
 
The authors estimate that the existing strategy would identify 71% of all HCV-infected 
people, and 44% of them would be cured over a lifetime. Compared to existing screening, 
a strategy of age 18 or older would result in 256,000 additional people identified, 28,000 
additional cures, and 4,400 fewer cases of hepatocellular liver cancer over the lifetime 
of this age group. For people born outside the baby boomer cohort, case detection rates 
would increase from 74% to 85%, and cure rates would increase from 49% to 61%. Overall, 
this would represent a 21% reduction in liver-attributable mortality, and an increase in life 
expectancy from 67.2 to 68.2 years among the affected population. 
All strategies decreased the costs related to managing chronic HCV and advanced liver  
disease. The cost of HCV testing in the existing strategy amounted to $2,500 per case  
diagnosed; in the 18 and over strategy, the cost of testing increased to $4,400 per case 
diagnosed. The 18 and over strategy was cost-effective, providing the greatest  
quality-adjusted life expectancy and the lowest cost/QALY gained ($28,000 per QALY). 
Figure 3 above also illustrates the importance of linking identified patients to care in an 
overall strategy that produces high cure rates. Schackman, Gutkind, Morgan, et al. (2018) 
modeled the cost-effectiveness of screening and treatment linkages in a high-risk  
population of patients in a methadone maintenance treatment (MMT) program, using data 
from a randomized trial. The study estimated costs and outcomes of on-site HCV screening 
and education or HCV screening, education, and active care coordination, compared to  
no intervention. The model took into account the probability of reinfection if patients  
engaged in injection drug use risk behavior.
As shown in Figure 4, on-site screening and education resulted in a projected 35% linking 
to care within six months and 31% achieving cure (sustained virologic response). Adding an 
active coordination component resulted in 60% linking and 54% achieving cure. The active 
care coordination intervention had a cost-effectiveness ratio of $24,600/QALY gained,  
compared to no intervention, and $76,500/QALY gained, compared to screening and 
education alone. Thus, the authors conclude that HCV care coordination interventions that 
include screening, education and active linkage to care in MMT settings are likely  
cost-effective at a conventional $100,000/QALY threshold. 
one-Time screening of 
all us adulTs would Be 
cosT-effecTive, providing 
The greaTesT qualiTy- 
adjusTed life expecTancy 
and lowesT cosT per  
qaly gained.
Source: Joshua A. Barocas, Abriana Tasillo, Golnaz Eftekhari Yazdi, Jianing Wang, Claudia Vellozzi, Susan 
Hariri, Cheryl Isenhour, Liisa Randall, John W. Ward, Jonathan Mermin, Joshua A. Salomon, Benjamin P. 
Linas. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based 
Hepatitis C Testing in the United States. Clinical Infectious Diseases, Volume 67, Issue 4, 1 August 2018, Pages 
549–556, https://doi.org/10.1093/cid/ciy098 
   Figure 4 
    Projected short-term and lifetime continuum of care results, by intervention group
In an economic analysis of a real-world HCV care coordination program in two New York 
City clinics, Behrends, Eggman, Gutkind, et al. (2018) found that the cost of a 5.6-month 
care coordination intervention was less than $800 including overhead. The authors  
proposed a three-part payment model tied to each phase of the program: enrollment to 
treatment initiation, treatment initiation to treatment completion, and a bonus payment 
for laboratory evidence of sustained viral response.
Policy Implications 
Hepatitis C treatment lies at the crossroads of science, economics, and policy. As Linas and 
Nolen (2018) note, with effective treatments in hand, the challenge has shifted from the 
biology of curing a virus to the public health problem of identifying and treating millions of 
HCV-infected people. 
The economics of the problem highlight the difference between cost-effectiveness, from 
the health system or societal perspective, and the budget impact for payers, especially 
public ones. There is considerable evidence that a variety of strategies for screening and 
treating HCV provide good value for their cost, at conventionally accepted standards for 
value. This is especially impressive given that the costs used in these analyses were higher 
than HCV treatments today; as competing medications enter the market, the cost of a cure 
has dropped from $84,000 to $26,400 (before discounts) for some regimens.
Screening recommendations from the CDC and USPSTF have increased HCV testing in  
clinical practice, especially among the baby boomer cohort that they target. However,  
evidence suggests that one-time testing of all people 18 and over would be more  
cost-effective, identify more cases, and yield greater cures. Given the impact of the  
previous change in CDC and USPSTF recommendations, changing them again would likely 
result in more screening and more treatment.
But what is cost-effective may not be affordable within specific budgets. Further, future  
savings may not accrue to the same payers that would have to absorb the considerable 
present costs of screening and treatment. This is particularly true for payers with  
disproportionately high prevalence of HCV infection in their populations, such as  
Medicaid and correctional institutions. 
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in economic models and 
real-world pracTice,  
idenTifying paTienTs wiTh 
hepaTiTis c and linking 
Them To early TreaTmenT 
provides good value for 
our healTh care dollar.
Source: Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman 
DC, Masson CL, Linas BP. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in 
US methadone maintenance treatment programs. Drug and Alcohol Dependence, 2018 Apr 1;185:411-420. doi: 
10.1016/j.drugalcdep.2017.11.031.
Given this context, some policymakers are exploring new ways to pay for HCV treatment. 
For example, the Secretary of Health in Louisiana is exploring a subscription-based  
payment model in which the state would pay a drug manufacturer a fixed purchase price  
for the length of a multi-year contract. The price would provide unlimited treatment access 
for people covered by Medicaid or in Louisiana’s correctional system. If structured  
properly, the model would allow the state to spread the costs of treatment across budget 
years, while expanding the manufacturer’s reach into populations that are not now being 
treated. 
The National Academies of Sciences, Engineering, and Medicine proposed a novel strategy 
that involves drug manufacturers competing to license their patent to the federal  
government for use in low-income and vulnerable populations. In that case, generic  
manufacturers could supply Medicaid and correctional institutions with HCV treatments  
at much lower cost, while protecting the market share of drug manufacturers in the private 
market.
Conclusion
In economic models and in real-world practice, identifying patients with hepatitis C  
infection and linking them to early treatment provides good value for our health care 
dollar. We conclude that: 
 1. Routine screening for HCV, without effort to identify risk factors, is cost-effective  
     and even cost-saving in some venues. 
 2. HCV treatment is cost-effective, even with high-cost medications and even with  
     high reinfection rates.
At this time, the question is not “should” we test and treat, but “how will we pay for it?” 
This is not a trivial question, but it is one that is best answered through financial  
instruments, not treatment restrictions. Rather than seek strategies that minimize cost by 
limiting treatment courses, health care systems and policymakers should negotiate  
aggressively holding the “chip” of large volume to drive down cost and should design  
financing schemes that help them to disperse cost over time.
aT This Time, The quesTion 
is noT should we TesT and 
TreaT, BuT how will we pay 
for iT.
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